Avatrombopag's FDA-approval prompts discussion of both the indication and drug itself. Finally, the publication of the SELECT-D study allows us to dig deeper into the data of a DOAC vs. LMWH in cancer-associated VTE.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
